Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors

This publication has 47 references indexed in Scilit:

• Liquid chromatography–tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma
  Journal of Chromatography B, 2013
• Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
  Biochemical Journal, 2012
• Design, Synthesis and Antiproliferative Activity of Novel 2-Substituted-4-amino-6-halogenquinolines
  Molecules, 2012
• Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors
  Bioorganic & Medicinal Chemistry, 2011
• Synthesis and antitumor activity of novel 6-aryl and 6-alkylpyrazolo[3,4-d]pyrimidin-4-one derivatives
  European Journal of Medicinal Chemistry, 2010
• Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: Synthesis and biological evaluation
  Bioorganic & Medicinal Chemistry, 2010
• Novel pyrazole derivatives: Synthesis and evaluation of anti-angiogenic activity
  Bioorganic & Medicinal Chemistry, 2010
• A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
  Expert Opinion on Pharmacotherapy, 2009
• Gefitinib (ZD1839, Iressa^®) in non‐small‐cell lung cancer: a review of clinical trials from a daily practice perspective
  Fundamental & Clinical Pharmacology, 2005
• Chemistry of Substituted Quinolinones. Part VI. Synthesis and Nucleophilic Reactions of 4-Chloro-8-methylquinolin-2(1H)-one and its Thione Analogue
  Molecules, 2000